A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-01

Study Completion Date

2024-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a single-center, open-lable and fixed sequence test conducted in healthy subjects to evaluate the pharmacokinetic effects of Itraconazole and Rifampicin on a single dose of SY-5007 Oral administration. It is planned to enroll 28 healthy subjects and assign them to two parallel test groups, Group A (SY-5007 combined with Itraconazole) and Group B (SY-5007 combined with Rifampicin).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults

NCT02729467

Healthy

COMPLETED PHASE1

Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects

NCT03301181

Healthy Volunteers: Asian, Non-Asian

COMPLETED PHASE1

A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants

NCT05057949

Healthy Volunteers

COMPLETED PHASE1

The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028

NCT04808648

Healthy Male Volunteers

UNKNOWN PHASE1

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

NCT07018635

Healthy Participants

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 28 evaluable healthy male subjects will be enrolled in this study. The subjects will be divided into two groups, A and B, with 14 people in each group.

In the itraconazole study (Group A), patients received single-dose SY-5007 80 mg on Day 1 and Day 11 and itraconazole 200 mg once or twice daily on Day 8-Day 18 orally.

In the rifampicin study (Group B), patients received single-dose SY-5007 160mg on Day 1 and Day 16 and rifampicin 600 mg once daily on Day 8-Day 21 orally.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A, Treatment Sequence (SY-5007-SY-5007/Itraconazole)

SY-5007 80mg, tablets, once daily on Day 1 and Day 11 before meal; Itraconazole 200mg, once or twice daily from Day 8 to Day 18.

Group Type EXPERIMENTAL

SY-5007

Intervention Type DRUG

SY-5007 80 mg, Tablets, 2 discrete single doses at Day 1 and Day 11

Itraconazole

Intervention Type DRUG

Itraconazole 200 mg, Capsules, Day 8-Day 18

Group B, Treatment Sequence (SY-5007-SY-5007/Rifampin)

SY-5007 160mg, tablets, once daily on Day 1 and Day 16 before meal, Rifampicin 600mg, once daily from Day 8 to Day 21.

Group Type EXPERIMENTAL

SY-5007

Intervention Type DRUG

SY-5007 160 mg, Tablets, 2 discrete single doses at Day 1 and Day 16

Rifampin

Intervention Type DRUG

Rifampin 600 mg, Capsules, Day 8-Day 21

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SY-5007

SY-5007 80 mg, Tablets, 2 discrete single doses at Day 1 and Day 11

Intervention Type DRUG

Itraconazole

Itraconazole 200 mg, Capsules, Day 8-Day 18

Intervention Type DRUG

SY-5007

SY-5007 160 mg, Tablets, 2 discrete single doses at Day 1 and Day 16

Intervention Type DRUG

Rifampin

Rifampin 600 mg, Capsules, Day 8-Day 21

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Fully understand the purpose, nature, methods, and potential adverse reactions of the trial, voluntarily participate, and sign a written informed consent form (ICF), and be able to follow the protocol requirements to complete the study as healthy subjects.
2. Male subjects aged ≥18 and ≤45 years old (including boundary values, based on the time of signing the informed consent form).
3. Body weight ≥50kg, and body mass index (BMI = weight/height\^2, kg/m\^2) between 18 and 26 kg/m\^2 (including boundary values).
4. Qualified subjects of reproductive capability must agree with their sexual partners to adopt a medically accepted contraceptive measure (such as intrauterine device, contraceptive pills, or condoms) during the trial and for 3 months after the end of the trial, and have no plans to donate sperm/eggs during the trial and for 3 months after the end of the trial.

Exclusion Criteria

Subjects will be ineligible for this study if they meet any of the following criteria:

1. Clear history of severe allergies, non-allergic drug reactions, or multiple drug allergies, or known hypersensitivity reactions to the investigational drug (active pharmaceutical ingredient or excipients).
2. Positive for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen, hepatitis C antibodies, or syphilis treponema antibodies at screening.
3. Presence of clinically significant abnormal vital signs, physical examination findings, laboratory test results, or electrocardiogram results at screening.
4. Currently suffering from or known by the investigator to have chronic gastrointestinal, liver, or kidney diseases that may affect trial outcomes.
5. Symptoms or medical history of any major diseases, including but not limited to cardiovascular, hepatic, renal diseases, or other acute or chronic gastrointestinal diseases, respiratory diseases, musculoskeletal diseases, as well as diseases of the blood, endocrine, nervous, or psychiatric systems, or any other conditions or physiological states that may interfere with trial results.
6. Any surgical conditions or conditions that may significantly affect drug absorption, distribution, metabolism, and excretion, or any surgical conditions or conditions that may pose harm to subjects participating in the trial, such as a history of gastrointestinal surgery (gastrectomy, gastrojejunal anastomosis, intestinal resection, etc.), urinary tract obstruction or difficulty in urination, history of digestive tract ulcers, gastrointestinal bleeding, etc. (Subjects who have undergone appendectomy or hernia repair surgery can be enrolled in the study).
7. Known or suspected history of drug abuse within the past two years at screening, or drug abuse within the past three months at screening or baseline, or positive drug abuse screening during screening or baseline.
8. Underwent major surgery within the past six months before the first dose or planning to undergo surgery during the trial.
9. Smoked an average of more than 5 cigarettes per day within the past three months before the first dose or unwilling to stop using any tobacco products during the trial.
10. Regularly consumed alcohol within the past three months before the first dose (defined as consuming more than 14 units of alcohol per week, with 1 unit equal to 360 mL of beer with an alcohol content of 5%, or 45 mL of spirits with an alcohol content of 40%, or 150 mL of wine with an alcohol content of 12%), or unable to stop drinking during the trial, or positive alcohol breath test at screening.
11. History of blood donation or significant blood loss (≥300 mL) within the past two years before the first dose, or use of blood products or receiving blood transfusions within the past month before the first dose.
12. Participated in other drug or medical device clinical trials within the past three months before the first dose (excluding those screened but ultimately not enrolled), or used the study drug before.
13. Received vaccination or inactivated vaccines within the past month before the first dose.
14. Used any prescription drugs, non-prescription drugs, health products, or herbal medicines within the past two weeks before the first dose (if the half-life (t1/2) of the drug used can be confirmed, the washout period should be ≥5 t1/2, with the longer one taken).
15. Habitually consumed grapefruit juice or excessive amounts (more than 8 cups, 1 cup = 250 mL) of tea, coffee, and/or caffeinated beverages and unable to stop drinking for at least 48 hours before the first dose and during the trial.
16. Have special dietary requirements or difficulty swallowing.
17. Difficulty in blood sampling, or a history of fainting or intolerance to venipuncture.
18. Clear history of neurological or psychiatric disorders, including dementia or epilepsy, etc.
19. Diagnosis of malignant tumors within the past five years (excluding cured in situ cancers, such as non-melanoma skin cancers).
20. For scientific reasons, compliance reasons, or for the safety of the subjects, the investigator deems it inappropriate for the subject to participate in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes